Researchers found very little difference in the outcomes of patients hospitalized with acute kidney injuries who received different antibiotics — cefepime or piperacillin-tazobactam — as treatment, according to the study published Oct. 14 in JAMA.
However, researchers did find that neurological dysfunction as a secondary outcome was more commonly seen in patients who had received cefepime.
"Patients in the cefepime group experienced fewer days alive and free of delirium and coma within 14 days than those in the piperacillin-tazobactam group," the University of Minnesota's Center for Infectious Disease Research and Policy wrote of the study.